Legal and health variations in drug litigation injunctions granted in Minas Gerais

Detalhes bibliográficos
Autor(a) principal: Coelho, Tiago Lopes
Data de Publicação: 2014
Outros Autores: Ferré, Felipe, Campos Neto, Orozimbo Henriques, Acurcio, Francisco de Assis, Cherchiglia, Mariângela Leal, Andrade, Eli Iola Gurgel
Tipo de documento: Artigo
Idioma: eng
por
Título da fonte: Revista de Saúde Pública
Texto Completo: https://www.revistas.usp.br/rsp/article/view/86922
Resumo: OBJECTIVE To investigate the factors related to the granting of preliminary court orders [injunctions] in drug litigations. METHODS A retrospective descriptive study of drug lawsuits in the State of Minas Gerais, Southeastern Brazil, was conducted from October 1999 to 2009. The database consists of 6,112 lawsuits, out of which 6,044 had motions for injunctions and 5,167 included the requisition of drugs. Those with more than one beneficiary were excluded, which totaled 5,072 examined suits. The variables for complete, partial, and suppressed motions were treated as dependent and assessed in relation to those that were independent – lawsuits (year, type, legal representation, defendant, court in which it was filed, adjudication time), drugs (level five of the anatomical therapeutic chemical classification), and diseases (chapter of the International Classification of Diseases). Statistical analyses were performed using the Chi-square test. RESULTS Out of the 5,072 lawsuits with injunctions, 4,184 (82.5%) had the injunctions granted. Granting varied from 95.8% of the total lawsuits in 2004 to 76.9% in 2008. Where there was legal representation, granting exceeded 80.0% and in lawsuits without representation, it did not exceed 66.9%. In public civil actions (89.1%), granting was higher relative to ordinary lawsuits (82.8%) and injunctions (80.1%). Federal courts granted only 68.6% of the injunctions, while the state courts granted 84.8%. Diseases of the digestive system and neoplasms received up to 87.0% in granting, while diseases of the nervous system, mental and behavioral disorders, and diseases of the skin and subcutaneous tissue received granting below 78.6% and showed a high proportion of suspended injunctions (10.9%). Injunctions involving paroxetine, somatropin, and ferrous sulfate drugs were all granted, while less than 54.0% of those involving escitalopram, sodium diclofenac, and nortriptyline were granted. CONCLUSIONS There are significant differences in the granting of injunctions, depending on the procedural and clinical variances. Important trends in the pattern of judicial action were observed, particularly, in the reduced granting [of injunctions] over the period.
id USP-23_a536f1e237ec7d17bc45aec8b4cb31bd
oai_identifier_str oai:revistas.usp.br:article/86922
network_acronym_str USP-23
network_name_str Revista de Saúde Pública
repository_id_str
spelling Legal and health variations in drug litigation injunctions granted in Minas Gerais Variáveis jurídicas e de saúde no deferimento de liminares por medicamentos em Minas Gerais OBJECTIVE To investigate the factors related to the granting of preliminary court orders [injunctions] in drug litigations. METHODS A retrospective descriptive study of drug lawsuits in the State of Minas Gerais, Southeastern Brazil, was conducted from October 1999 to 2009. The database consists of 6,112 lawsuits, out of which 6,044 had motions for injunctions and 5,167 included the requisition of drugs. Those with more than one beneficiary were excluded, which totaled 5,072 examined suits. The variables for complete, partial, and suppressed motions were treated as dependent and assessed in relation to those that were independent – lawsuits (year, type, legal representation, defendant, court in which it was filed, adjudication time), drugs (level five of the anatomical therapeutic chemical classification), and diseases (chapter of the International Classification of Diseases). Statistical analyses were performed using the Chi-square test. RESULTS Out of the 5,072 lawsuits with injunctions, 4,184 (82.5%) had the injunctions granted. Granting varied from 95.8% of the total lawsuits in 2004 to 76.9% in 2008. Where there was legal representation, granting exceeded 80.0% and in lawsuits without representation, it did not exceed 66.9%. In public civil actions (89.1%), granting was higher relative to ordinary lawsuits (82.8%) and injunctions (80.1%). Federal courts granted only 68.6% of the injunctions, while the state courts granted 84.8%. Diseases of the digestive system and neoplasms received up to 87.0% in granting, while diseases of the nervous system, mental and behavioral disorders, and diseases of the skin and subcutaneous tissue received granting below 78.6% and showed a high proportion of suspended injunctions (10.9%). Injunctions involving paroxetine, somatropin, and ferrous sulfate drugs were all granted, while less than 54.0% of those involving escitalopram, sodium diclofenac, and nortriptyline were granted. CONCLUSIONS There are significant differences in the granting of injunctions, depending on the procedural and clinical variances. Important trends in the pattern of judicial action were observed, particularly, in the reduced granting [of injunctions] over the period. OBJETIVO Investigar fatores relacionados ao deferimento de liminares por medicamentos. MÉTODOS Estudo descritivo retrospectivo dos processos judiciais por medicamentos em Minas Gerais, de outubro de 1999 a 2009. A base de dados, constituída por 6.112 ações judiciais, teve 6.044 com pedido de liminar e 5.167 com requisição de medicamentos. Foram excluídas as ações que continham mais de um beneficiário, totalizando 5.072 ações analisadas. As variáveis deferimento total, parcial e suspensão foram tratadas como dependentes e avaliadas em relação às independentes: processo (ano, tipo de ação, representação judicial, réu, justiça de ajuizamento, tempo de decisão judicial), medicamentos (nível 5 da Anatomical Therapeutic Chemical) e doença (por capítulo da Classificação Internacional de Doenças. As análises estatísticas foram realizadas pelo teste Qui-quadrado. RESULTADOS Dentre as 5.072 ações com liminares, 4.184 (82,5%) foram deferidas. O deferimento variou de 95,8% em 2004 a 76,9% em 2008. Quando houve representação judicial, o deferimento superou 80,0%; nas ações sem representação, não ultrapassou 66,9%. Nas ações civis públicas (89,1%) o deferimento foi superior ao verificado em ações ordinárias (82,8%) e nos mandados de segurança (80,1%). A Justiça Federal deferiu apenas 68,6% das liminares, contra 84,8% da Justiça Estadual. Doenças do aparelho digestivo e neoplasias apresentaram deferimento acima de 87,0%, enquanto doenças do sistema nervoso, transtornos mentais e comportamentais e doenças da pele e do tecido celular subcutâneo tiveram deferimento inferior a 78,6% e apresentaram elevada proporção de liminares suspensas (10,9%). Os fármacos paroxetina, somatropina e sulfato ferroso tiveram 100% de deferimento. Escitalopram, diclofenaco de sódio e nortriptilina obtiveram deferimento inferior a 54,0%. CONCLUSÕES Há diferença significativa no deferimento das liminares a partir de variáveis processuais e clínicas. Tendências importantes no padrão de atuação judicial foram observadas, particularmente a redução do deferimento ao longo do período. Universidade de São Paulo. Faculdade de Saúde Pública2014-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://www.revistas.usp.br/rsp/article/view/8692210.1590/S0034-8910.2014048005286Revista de Saúde Pública; Vol. 48 No. 5 (2014); 808-816Revista de Saúde Pública; Vol. 48 Núm. 5 (2014); 808-816Revista de Saúde Pública; v. 48 n. 5 (2014); 808-8161518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPengporhttps://www.revistas.usp.br/rsp/article/view/86922/89891https://www.revistas.usp.br/rsp/article/view/86922/89892Copyright (c) 2017 Revista de Saúde Públicainfo:eu-repo/semantics/openAccessCoelho, Tiago Lopes Ferré, Felipe Campos Neto, Orozimbo Henriques Acurcio, Francisco de Assis Cherchiglia, Mariângela Leal Andrade, Eli Iola Gurgel 2014-11-04T11:58:11Zoai:revistas.usp.br:article/86922Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2014-11-04T11:58:11Revista de Saúde Pública - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Legal and health variations in drug litigation injunctions granted in Minas Gerais
Variáveis jurídicas e de saúde no deferimento de liminares por medicamentos em Minas Gerais
title Legal and health variations in drug litigation injunctions granted in Minas Gerais
spellingShingle Legal and health variations in drug litigation injunctions granted in Minas Gerais
Coelho, Tiago Lopes
title_short Legal and health variations in drug litigation injunctions granted in Minas Gerais
title_full Legal and health variations in drug litigation injunctions granted in Minas Gerais
title_fullStr Legal and health variations in drug litigation injunctions granted in Minas Gerais
title_full_unstemmed Legal and health variations in drug litigation injunctions granted in Minas Gerais
title_sort Legal and health variations in drug litigation injunctions granted in Minas Gerais
author Coelho, Tiago Lopes
author_facet Coelho, Tiago Lopes
Ferré, Felipe
Campos Neto, Orozimbo Henriques
Acurcio, Francisco de Assis
Cherchiglia, Mariângela Leal
Andrade, Eli Iola Gurgel
author_role author
author2 Ferré, Felipe
Campos Neto, Orozimbo Henriques
Acurcio, Francisco de Assis
Cherchiglia, Mariângela Leal
Andrade, Eli Iola Gurgel
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Coelho, Tiago Lopes
Ferré, Felipe
Campos Neto, Orozimbo Henriques
Acurcio, Francisco de Assis
Cherchiglia, Mariângela Leal
Andrade, Eli Iola Gurgel
description OBJECTIVE To investigate the factors related to the granting of preliminary court orders [injunctions] in drug litigations. METHODS A retrospective descriptive study of drug lawsuits in the State of Minas Gerais, Southeastern Brazil, was conducted from October 1999 to 2009. The database consists of 6,112 lawsuits, out of which 6,044 had motions for injunctions and 5,167 included the requisition of drugs. Those with more than one beneficiary were excluded, which totaled 5,072 examined suits. The variables for complete, partial, and suppressed motions were treated as dependent and assessed in relation to those that were independent – lawsuits (year, type, legal representation, defendant, court in which it was filed, adjudication time), drugs (level five of the anatomical therapeutic chemical classification), and diseases (chapter of the International Classification of Diseases). Statistical analyses were performed using the Chi-square test. RESULTS Out of the 5,072 lawsuits with injunctions, 4,184 (82.5%) had the injunctions granted. Granting varied from 95.8% of the total lawsuits in 2004 to 76.9% in 2008. Where there was legal representation, granting exceeded 80.0% and in lawsuits without representation, it did not exceed 66.9%. In public civil actions (89.1%), granting was higher relative to ordinary lawsuits (82.8%) and injunctions (80.1%). Federal courts granted only 68.6% of the injunctions, while the state courts granted 84.8%. Diseases of the digestive system and neoplasms received up to 87.0% in granting, while diseases of the nervous system, mental and behavioral disorders, and diseases of the skin and subcutaneous tissue received granting below 78.6% and showed a high proportion of suspended injunctions (10.9%). Injunctions involving paroxetine, somatropin, and ferrous sulfate drugs were all granted, while less than 54.0% of those involving escitalopram, sodium diclofenac, and nortriptyline were granted. CONCLUSIONS There are significant differences in the granting of injunctions, depending on the procedural and clinical variances. Important trends in the pattern of judicial action were observed, particularly, in the reduced granting [of injunctions] over the period.
publishDate 2014
dc.date.none.fl_str_mv 2014-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rsp/article/view/86922
10.1590/S0034-8910.2014048005286
url https://www.revistas.usp.br/rsp/article/view/86922
identifier_str_mv 10.1590/S0034-8910.2014048005286
dc.language.iso.fl_str_mv eng
por
language eng
por
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rsp/article/view/86922/89891
https://www.revistas.usp.br/rsp/article/view/86922/89892
dc.rights.driver.fl_str_mv Copyright (c) 2017 Revista de Saúde Pública
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2017 Revista de Saúde Pública
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
dc.source.none.fl_str_mv Revista de Saúde Pública; Vol. 48 No. 5 (2014); 808-816
Revista de Saúde Pública; Vol. 48 Núm. 5 (2014); 808-816
Revista de Saúde Pública; v. 48 n. 5 (2014); 808-816
1518-8787
0034-8910
reponame:Revista de Saúde Pública
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista de Saúde Pública
collection Revista de Saúde Pública
repository.name.fl_str_mv Revista de Saúde Pública - Universidade de São Paulo (USP)
repository.mail.fl_str_mv revsp@org.usp.br||revsp1@usp.br
_version_ 1800221795926671360